Literature DB >> 11487392

Seroepidemiology of low and high oncogenic risk types of human papillomavirus in a predominantly male cohort of STD clinic patients.

J Slavinsky1, P Kissinger, L Burger, A Boley, R P DiCarlo, M E Hagensee.   

Abstract

Human papillomaviruses (HPV) infecting the genital tract are associated with warts and anogenital malignancies. Although HPV is a highly prevalent sexually transmitted disease (STD), the majority of research has focused on female cohorts due to gender specific sequelae. Our objective was to measure the epidemiological features and seroprevalences of HPV-6/11 and 16 in a predominantly male group of STD clinic patients. High-risk individuals (n=687), who attended the public STD clinic were administered a behavioural questionnaire and serum tested for antibodies against HPV-6/11 and HPV-16 capsids via capture enzyme-linked immunosorbent assay. Despite the male predominance in this study, women were significantly more likely to have antibodies against both HPV-6/11 and HPV-16. Condom use appeared to be partially protective against HPV-16 seropositivity only. In conclusion, despite exhibiting increased risk behaviour, men were less likely to be HPV seropositive. Additional studies utilizing male cohorts are warranted to further elucidate this phenomenon.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11487392     DOI: 10.1258/0956462011923615

Source DB:  PubMed          Journal:  Int J STD AIDS        ISSN: 0956-4624            Impact factor:   1.359


  16 in total

1.  Human papillomavirus 6 seropositivity is associated with risk of head and neck squamous cell carcinoma, independent of tobacco and alcohol use.

Authors:  C S Furniss; M D McClean; J F Smith; J Bryan; K M Applebaum; H H Nelson; M R Posner; K T Kelsey
Journal:  Ann Oncol       Date:  2008-12-15       Impact factor: 32.976

2.  Update on Human Papillomavirus (HPV) Vaccines: An Advisory Committee Statement (ACS) National Advisory Committee on Immunization (NACI) .

Authors:  Dr M Dawar; Ms T Harris; Dr S McNeil
Journal:  Can Commun Dis Rep       Date:  2012-01-02

3.  Serum antibody response following genital {alpha}9 human papillomavirus infection in young men.

Authors:  Zoe R Edelstein; Joseph J Carter; Ruchi Garg; Rachel L Winer; Qinghua Feng; Denise A Galloway; Laura A Koutsky
Journal:  J Infect Dis       Date:  2011-07-15       Impact factor: 5.226

4.  Gender and age-specific seroprevalence of human papillomavirus 16 and 18 in general population in Tehran, Iran.

Authors:  Arezoo Aghakhani; Setareh Mamishi; Shahram Sabeti; Farahnaz Bidari-Zerehpoosh; Mohammad Banifazl; Anahita Bavand; Amitis Ramezani
Journal:  Med Microbiol Immunol       Date:  2016-11-17       Impact factor: 3.402

5.  Oral human papillomavirus infection in men might contribute to HPV serology.

Authors:  S Syrjänen; T Waterboer; K Kero; J Rautava; K Syrjänen; S Grenman; M Pawlita
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-14       Impact factor: 3.267

Review 6.  EUROGIN 2014 roadmap: differences in human papillomavirus infection natural history, transmission and human papillomavirus-related cancer incidence by gender and anatomic site of infection.

Authors:  Anna R Giuliano; Alan G Nyitray; Aimée R Kreimer; Christine M Pierce Campbell; Marc T Goodman; Staci L Sudenga; Joseph Monsonego; Silvia Franceschi
Journal:  Int J Cancer       Date:  2014-07-26       Impact factor: 7.396

7.  Human papillomavirus (HPV) 6, 11, 16, and 18 seroprevalence is associated with sexual practice and age: results from the multinational HPV Infection in Men Study (HIM Study).

Authors:  Beibei Lu; Raphael P Viscidi; Ji-Hyun Lee; Yougui Wu; Luisa L Villa; Eduardo Lazcano-Ponce; Roberto J Carvalho da Silva; Maria Luiza Baggio; Manuel Quiterio; Jorge Salmerón; Danelle C Smith; Martha Abrahamsen; Mary Papenfuss; Heather G Stockwell; Anna R Giuliano
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-03-04       Impact factor: 4.254

8.  Human papillomavirus-specific antibody status in oral fluids modestly reflects serum status in human immunodeficiency virus-positive individuals.

Authors:  Jennifer E Cameron; Isaac V Snowhite; Anil K Chaturvedi; Michael E Hagensee
Journal:  Clin Diagn Lab Immunol       Date:  2003-05

9.  The use of human papillomavirus seroepidemiology to inform vaccine policy.

Authors:  Mark Schiffman; Mahboobeh Safaeian; Nicolas Wentzensen
Journal:  Sex Transm Dis       Date:  2009-11       Impact factor: 2.830

Review 10.  Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.

Authors:  Anna R Giuliano; Guillermo Tortolero-Luna; Elena Ferrer; Ann N Burchell; Silvia de Sanjose; Susanne Kruger Kjaer; Nubia Muñoz; Mark Schiffman; F Xavier Bosch
Journal:  Vaccine       Date:  2008-08-19       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.